New pill could ease rare lung disease

NCT ID NCT07365332

Recruiting now Disease control Sponsor: Inhibikase Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. About 486 adults will receive either IKT-001 or a placebo to see if the drug improves blood flow and walking distance. The goal is to find a new way to manage PAH symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IKT-001 (tablet)
What this could lead to: If successful, this could provide a new treatment option to help control pulmonary arterial hypertension and improve daily function.
What could go wrong: This is a Phase 3 trial, but results are not guaranteed. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Norton Healthcare
RECRUITING

Louisville, Kentucky, 40202, United States
Tufts Medical Center
RECRUITING

Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.